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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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The precious participation of the Huntington’s
disease community in the quest for treatments: a
report on the 2015 HD Therapeutics Conference
As long-awaited clinical trials of new drug candidates for Huntington’s
disease get underway, scientists have intensified collecting information
from research study participants to quickly and accurately test the
effectiveness of the potential remedies.
This was a major theme of the 10th Annual HD Therapeutics Conference,
held February 23-26 at the Parker Palm Springs hotel in Palm Springs, CA.
(Click here to read my initial report on science and solidarity, filed during
the conference.)
The event was sponsored by CHDI Foundation, Inc., a nonprofit, virtual
biotech focused solely on developing HD treatments and the largest source
of private HD research funding. Backed by wealthy donors, CHDI has an
annual budget of about $100 million.
“The thing that I’m keying on is what I would call human data,” Robert
Pacifici, Ph.D., CHDI’s chief scientific officer, told me in an interview on
February 26. “Obviously when we do drug discovery we think about a
variety of model systems – everything from worms to flies to zebrafish to
sheep and songbirds and everything in between.
“But we both know that the only organism that actually has Huntington’s
disease unfortunately is the human. So for a long time I’ve been saying that
there’s nothing more precious and valuable to a drug hunter than an
observation that’s actually made in the population that they seek to treat,
in our case Huntington’s patients.”
Dr. Pacifici recalled how genetic data from hundreds of people from
dozens of families led to the discovery of the huntingtin gene in 1993.
Thanks to those efforts, treatments aimed at lowering the amount of
mutant huntingtin RNA and protein in the brain cells of HD patients are
on the verge of entering clinical trials, he added.
“Now what we’re asking for is to really start getting more specific about the
observations [in humans] that we want to make and how we’re going to
leverage them,” Dr. Pacifici explained.
You can watch my interview with Dr. Pacific in the video below.
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Human Data 'Precious' for
Huntington's Disease Drug Hunters:
An Interview with Dr. Robert Pacifici
from Gene Veritas

19:44

Human Data 'Precious' for Huntington's Disease Drug Hunters: An
Interview with Dr. Robert Pacifici from Gene Veritas on Vimeo.
Key role of modifier genes
Dr. Pacifici cited two major examples of new human data revealed at the
conference that will a have profound impact on the quest for treatments.
“We’re literally at the precipice of identifying what are modifier genes,” he
said, referring to the research presented by Jong-Min Lee, Ph.D., of
Massachusetts General Hospital. “It’s just incredibly exciting to me.”
An abnormally expanded huntingtin gene is the principal cause of HD, but
other so-called modifier genes also help determine the age of disease
onset.
“Why is it that one person’s Huntington’s starts earlier than another?” Dr.
Pacifici asked. “That’s tragic.” More positively, it also means the other
person’s onset starts later. “Well, that’s exactly what we want a drug to do.”
Human data has played a major role, he pointed out. With thousands of
HD-affected people participating, researchers have been able to examine
their genetic composition, involving not just their Huntington’s gene, “but
their entire genome, to do what’s called a Genome Wide Association Study,
or GWAS, and figure out what it is that’s different about individuals that
causes one person’s Huntington’s to start earlier than another,” Dr. Pacifici
explained.
In his presentation titled “Medication of Huntington’s disease by genetic
variations,” Dr. Lee reported how the large research team seeking modifier
genes has narrowed its search to chromosomes 3, 8, and 15. (Located in all
of a human’s cells, the 46 chromosomes are long, twined strands of DNA
containing a person’s entire genetic heritage.) According to Dr. Lee,
chromosome 15 has both a “bad” and “good” modifier, with a six-year
difference in onset between individuals having one versus the other.
“If we can identify that [good] gene and figure out how it’s doing that, then
what we have is a very specific set of instructions for drug hunters to make
a compound that does that same thing,” Dr. Pacifici said.
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Jong-Min Lee, Ph.D. (photo by Gene Veritas)
‘Cheating a little bit’ with biomarkers
The second example involves cerebrospinal fluid (CSF), the liquid that
bathes the brain and circulates up and down the spine. Researchers have
been searching for HD-related biomarkers in samples of CSF taken from
volunteers afflicted with the disease as well as so-called premanifest
people, individuals who (like me) carry the gene but have yet to show
classic, easily notable symptoms such as involuntary movements (chorea
and other types).
Dr. Pacifici defined biomarkers as “a way of cheating a little bit” to get
signals without waiting for the more time-consuming and more expensive
later phases of a clinical trial.
The human brain can only be studied directly only after a person has died,
as pointed out in a talk on CSF by Ed Wild, M.D., Ph.D., of the University
College of London. Imaging methods such as MRI are helpful but very
limited. So scientists are putting ever greater emphasis on finding signals
in the CSF such as mutant huntingtin protein and other biomarkers.
CSF provides a “snapshot of what’s going on in the human brain,” Dr.
Pacifici observed, adding that it might indicate in a clinical trial whether a
huntingtin-lowering drug is having the desired effect.
Clinical trial administrators would still need to wait many months to get
meaningful observations about actual effects on symptoms, but seeing
what the drug does at the molecular level is a key first step.
“In other words, we don’t want to give the drug [. . .] and hope that after
three years of waiting that we’re going to have an effect,” he said. “We want
to know right away that that drug was doing the job that it was charged to
do, in this case lowering huntingtin levels.”
A CSF study
curehd.blogspot.com/2015/03/the-precious-participation-of.html
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Describing the analysis of CSF from HD patients in a research study of
twelve individuals that he helped direct, Dr. Wild observed that the closer
a premanifest individual was to probable onset, the higher the level of
mutant huntingtin found in the CSF. Similarly, among affected individuals
higher levels of the mutant protein correlated with worse symptoms.
Dr. Wild and other scientists are still striving to determine the specific
origin of the mutant huntingtin found in the CSF. At this point they
hypothesize that it comes from neurons, a specific type of brain cell.
Scientists aim to improve CSF collection efforts and obtain a clearer
understanding of what occurs in the CSF through a new, CHDI-funded
project called HDClarity. The initial research sites are at University College
of London, the University of British Columbia, and the University of Ulm,
Germany.
You can watch Dr. Wild’s presentation in the video below.

Biomarkers and Biological Insights
from Huntington's Disease Patient
Cerebrospinal Fluid
from Gene Veritas

33:31

Biomarkers and Biological Insights from Huntington's Disease Patient
Cerebrospinal Fluid from Gene Veritas on Vimeo.
The rise of clinical trials
The need for clinical trial volunteers will increase dramatically as the
number of trials grows rapidly.
With a total of nine active trials, 2014 had an “unprecedented amount of
activity in clinical trials in Huntington’s disease,” Ray Dorsey, M.D., a
professor of medicine at the University of Rochester and the president of
the Huntington Study Group, stated in an overview of recent HD trials.
These trials included the two largest-ever regarding HD: a study of
coenzyme Q10 with 609 participants and a study of creatine with 553
participants. Both were halted because of lack of efficacy, but helped
scientists understand the need for better evaluation of substances before
taking them into a trial, Dr. Dorsey noted.
Last year brought one of the few successes in HD clinical trial history: the
highly favorable results of Auspex Pharmaceuticals’ testing of its
compound SD-809, which reduces chorea substantially and with fewer and
milder side effects than its predecessor drug, tetrabenazine.
Presenting a chart of clinical trial trends, Dr. Dorsey demonstrated that the
number of HD trials is growing exponentially: from four trials in 19992002 to 28 trials in the period 2011-2014.
curehd.blogspot.com/2015/03/the-precious-participation-of.html
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“I think we’re poised for success,” he concluded.

10th Annual HD Therapeutics Conference participants watch a
presentation (photo by Gene Veritas)
Assessing the potential of gene-silencing
In reviewing the clinical trial outlook for 2015, CHDI’s consulting medical
director, Bernhard Landwehrmeyer, M.D., Ph.D., noted the continued
upward trend, with six active trials.
Dr. Landwehrmeyer described the plans for a Phase I gene-silencing
clinical trial by Isis Pharmaceuticals, Inc., and Roche. This approach seeks
to attack the causes of the disease at its roots (click here to read more).
Isis’s senior vice president for research, Frank Bennett, Ph.D., stated in his
conference presentation that the trial would begin by the end of the second
quarter, but Dr. Landwehrmeyer predicted it would start later in the year.
It is only the very first step in gene-silencing treatments for HD, he
stressed.
Nevertheless, he observed that many other companies and labs are
working on their own versions of gene-silencing treatments for HD. The
chart he displayed showed 14 other entities in addition to Roche and Isis.
“It’s important that we have such a rich toolbox in attempts to make genesilencing a therapeutic reality,” Dr. Landwehrmeyer said.
He noted that the Isis/Roche trial is unusual because it must include
symptomatic patients, who will receive the gene-silencing drug via a spinal
tap. Typically a Phase I trial accepts only healthy volunteers because it is
testing for safety and tolerability, not for efficacy.
The trial will take place at HD centers in England, Canada, and Germany
that have in-patient intensive care monitoring facilities, he noted.
Dr. Landwehrmeyer said it was important to set realistic expectations for
the HD community, which anxiously awaits good news about genesilencing because of its potential to significantly impact the disease.
“You are NOT missing the boat, if you do not participate in the Isis study,”
he said, referring to HD-affected individuals. Establishing safe and
effective gene-silencing therapies for HD will still take “decades.”
Once trials prove them to be safe and effective, these drugs can reach the
market and become available to all HD families.
curehd.blogspot.com/2015/03/the-precious-participation-of.html
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Bernhard Landwehrmeyer, M.D., Ph.D. (photo by Gene Veritas)
Big challenges remain
Dr. Landwehrmeyer also commented on the other trials taking place this
year: Pride-HD (to test pridopidine); APACHE and Amaryllis (to test
“Viagra for the brain”); LEGATO-HD (to test laquinimod); and a
forthcoming trial in deep brain stimulation.
In all, he noted, at least 1,500 HD patients are expected to take part in
clinical trials this year.
“That’s on the one hand fantastic,” he said. “But timely recruitment into
these studies has become an issue.”
Some HD study centers are underutilized, while others are overloaded, he
noted. The number of trial participants is further restricted by
inclusion/exclusion criteria (for example, the particular disease stage of
the patient). Pharmaceutical companies should enhance a “culture of
cooperation” regarding trials, he said, and regional and national patient
advocacy organizations need to activate their networks.
Enroll-HD, the global platform, research project, and family registry aimed
at facilitating clinical trials and the discovery of treatments, recently
reached a milestone with its 5,000th registrant, but needs to grow to as
many as 30,000, Dr. Landwehrmeyer observed.
Hoping for an end to conferences – and HD
The 10th Annual HD Therapeutics Conference had numerous other
compelling presentations on the search for treatments. Click here to visit
my video album, where you can view many of the presentations.
The conference also featured some 90 posters detailing cutting-edge HD
research projects.
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Conference attendees view posters of Huntington's disease research
projects (photo by Gene Veritas)
“Obviously we’re a time-motivated organization, and we know patients are
waiting,” Dr. Pacifici said. “So the fact that it’s taken us ten years to get to
this stage is not necessarily something to celebrate. That said, I think we
should pay homage to the progress that’s been made over that period of
time.”
Dr. Pacifici observed that with well-designed clinical trials, “it’s really an
exciting time” in the quest for treatments.
He said that he was struck by the courage and collaborative spirit of the
community, from academia to the private sector to the families. He also
thanked HD families and their supporters for their participation in
research studies, clinical trials, and other activities.
“This isn’t a competition,” he declared. “This is an opportunity for all of us
to enable each other, which I don’t take for granted, because one of the
potential downsides of getting to the endgame – which we are – is that’s
when people start to be a little more secretive and a little bit more
protective. We saw here time and again even multinational pharmaceutical
and biotech companies standing up at our conference and presenting new,
unpublished findings so that everybody could benefit from them.”
Along the way, failures will occur, because drug discovery is a very
inefficient process, he emphasized. (Only one in ten clinical trials results in
a marketable drug.)
“That’s frustrating,” he recognized. “Don’t be disheartened. Know that we
have a large and deep portfolio [and] that we’re going to learn from each
one of these failures. I think, and I have every confidence, that we’re going
to start getting real positive signals that then we can build on. And that’s
when the fun starts.
“I hope we’re sitting here together again next year for the eleventh
conference, but I also hope we’re not sitting down here for too many more.
And I mean that in a positive way.”
***
For additional coverage of the conference, visit HDBuzz.net.
(Disclosure: I hold a small number of shares of stock in Isis
Pharmaceuticals, Inc.)
Posted by Gene Veritas at 11:20 PM
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2 comments:
Caitlin said...
Hi,
Thank you so much for this excellent summary of the
conference. Would it be ok to share your article (crediting you,
of course) with our Huntingtons Queensland community in our
quarterly newsletter?
4:58 PM, March 31, 2015

Gene Veritas said...
Caitlin, yes, please do share! Gene
11:47 AM, May 11, 2015
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